Clinical Trial Detail

NCT ID NCT02756364
Title MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Millennium Pharmaceuticals, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Sapanisertib

Fulvestrant

Age Groups: senior adult

Additional content available in CKB BOOST